Oncoinvent Investor Relations Material
Latest events
M&A Announcement
Oncoinvent
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Oncoinvent
Access all reports
Oncoinvent is a biotechnology company focused on the research and development of radiopharmaceuticals for the treatment of cancer. The company specializes in designing targeted therapies that deliver radioactive isotopes directly to cancerous tissues, with the goal of enhancing the precision and effectiveness of treatment while minimizing damage to surrounding healthy cells. Oncoinvent’s core technology platform supports the development of injectable products for intraperitoneal and other localized delivery methods. The company serves the healthcare and pharmaceutical sectors through its proprietary research initiatives. The company is headquartered in Oslo, Norway, and its shares are listed on the NOTC.
Key slides for Oncoinvent
M&A Announcement
Oncoinvent
M&A Announcement
Oncoinvent
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
ONCIN
Country
🇳🇴 Norway